Literature DB >> 6193537

Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374, in the monkey (Macaca fascicularis).

W Krause, M Schubert, M Totzek.   

Abstract

The pharmacokinetics of ZK 36 374 after intravenous, oral and topical administrations to female monkeys has been investigated using tritium-labelled drug. Following intravenous injection of 2 and 200 microgram/kg a triphasic decline in the plasma levels of labelled compounds was observed with half-lives of 45 min, 4.3 h and 1.7 d. The half-life of the unchanged drug was 13 min. Almost 10% of an oral dose of 200 microgram/kg were bioavailable exhibiting maximum plasma levels of 5.7 +/- 3.6 ng/ml. The drug was totally metabolized and excreted mainly with the urine in the form of more than 10 metabolites. Following topical application of 1 mg, 5.5 +/- 2.2% of the dose was percutaneously absorbed using a TRIS-buffered solution of ZK 36 374 and 1.3 +/- 0.2% was absorbed applying an ethanolic solution of the drug. The plasma levels of labelled compounds were practically constant during the whole observation period of 36 hours.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193537     DOI: 10.1016/0262-1746(83)90044-6

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  3 in total

1.  Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms.

Authors:  M Hildebrand; T Staks; B Nieuweboer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.